Stephan Von Haehling
#129,781
Most Influential Person Now
Stephan Von Haehling's AcademicInfluence.com Rankings
Stephan Von Haehlingphilosophy Degrees
Philosophy
#6263
World Rank
#9267
Historical Rank
Logic
#3443
World Rank
#4599
Historical Rank
Download Badge
Philosophy
Stephan Von Haehling's Degrees
- Doctorate Medicine University of Göttingen
- PhD Medicine University of Göttingen
Why Is Stephan Von Haehling Influential?
(Suggest an Edit or Addition)Stephan Von Haehling's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Frailty consensus: a call to action. (2013) (2719)
- Sarcopenia with limited mobility: an international consensus. (2011) (848)
- An overview of sarcopenia: facts and numbers on prevalence and clinical impact (2010) (634)
- Inflammatory mediators in chronic heart failure: an overview (2004) (609)
- Welcome to the ICD‐10 code for sarcopenia (2016) (505)
- Altered intestinal function in patients with chronic heart failure. (2007) (491)
- Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. (2010) (485)
- Muscle wasting in patients with chronic heart failure: results from the studies investigating co-morbidities aggravating heart failure (SICA-HF). (2013) (448)
- Cachexia as a major underestimated and unmet medical need: facts and numbers (2010) (442)
- Ethical guidelines for publishing in the journal of cachexia, sarcopenia and muscle: update 2017 (2017) (420)
- Prevalence, incidence, and clinical impact of sarcopenia: facts, numbers, and epidemiology—update 2014 (2014) (414)
- Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. (2007) (398)
- Ethical guidelines for publishing in the Journal of Cachexia, Sarcopenia and Muscle: update 2019 (2019) (368)
- ICU-acquired weakness and recovery from critical illness. (2014) (365)
- Cardiac cachexia: a systematic overview. (2009) (326)
- Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives (2012) (324)
- Sarcopenia: A Time for Action. An SCWD Position Paper (2019) (288)
- Nutrition, metabolism, and the complex pathophysiology of cachexia in chronic heart failure. (2007) (286)
- The effect of micronutrient supplementation on quality-of-life and left ventricular function in elderly patients with chronic heart failure. (2005) (286)
- The role of myostatin in muscle wasting: an overview (2011) (276)
- Prevalence, incidence and clinical impact of cachexia: facts and numbers—update 2014 (2014) (265)
- Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure. (2005) (260)
- Effects of intravenous iron therapy in iron‐deficient patients with systolic heart failure: a meta‐analysis of randomized controlled trials (2016) (258)
- C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study. (2009) (219)
- Iron deficiency predicts impaired exercise capacity in patients with systolic chronic heart failure. (2011) (218)
- Iron status in patients with chronic heart failure. (2013) (216)
- Increased indoleamine 2,3-dioxygenase (IDO) activity and elevated serum levels of tryptophan catabolites in patients with chronic kidney disease: a possible link between chronic inflammation and uraemic symptoms. (2009) (212)
- Biomarkers for physical frailty and sarcopenia: state of the science and future developments (2015) (211)
- Stroke induced Sarcopenia: muscle wasting and disability after stroke. (2013) (195)
- Statins for heart failure: at the crossroads between cholesterol reduction and pleiotropism? (2004) (193)
- The Role of Nutraceuticals in Statin Intolerant Patients. (2018) (191)
- Studies on bacterial endotoxin and intestinal absorption function in patients with chronic heart failure. (2012) (187)
- Prevalence and clinical impact of cachexia in chronic illness in Europe, USA, and Japan: facts and numbers update 2016 (2016) (183)
- Iron Deficiency in Heart Failure: An Overview. (2019) (168)
- Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio‐Oncology Council of the European Society of Cardiology (ESC) (2020) (165)
- Increased 90-Day Mortality in Patients With Acute Heart Failure With Elevated Copeptin: Secondary Results From the Biomarkers in Acute Heart Failure (BACH) Study (2011) (156)
- Prevention of liver cancer cachexia-induced cardiac wasting and heart failure. (2014) (153)
- Ethical guidelines for publishing in the Journal of Cachexia, Sarcopenia and Muscle: update 2015 (2015) (152)
- Intestinal blood flow in patients with chronic heart failure: a link with bacterial growth, gastrointestinal symptoms, and cachexia. (2014) (150)
- Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure. (2007) (150)
- The effects of a high-caloric protein-rich oral nutritional supplement in patients with chronic heart failure and cachexia on quality of life, body composition, and inflammation markers: a randomized, double-blind pilot study (2010) (149)
- Intestinal congestion and right ventricular dysfunction: a link with appetite loss, inflammation, and cachexia in chronic heart failure. (2016) (146)
- Sarcopenia in patients with heart failure with preserved ejection fraction: Impact on muscle strength, exercise capacity and quality of life. (2016) (145)
- From sarcopenia to frailty: a road less traveled (2014) (144)
- From muscle wasting to sarcopenia and myopenia: update 2012 (2012) (142)
- Body mass index and prognosis in patients hospitalized with acute exacerbation of chronic obstructive pulmonary disease (2011) (140)
- Ethical guidelines for authorship and publishing in the Journal of Cachexia, Sarcopenia and Muscle (2010) (133)
- The emerging role of the gut in chronic heart failure (2008) (131)
- Cachexia as a major public health problem: frequent, costly, and deadly (2013) (120)
- Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio‐Oncology Study Group of the Heart Failure Association and the Cardio‐Oncology Council of the European Society of Cardiology (2020) (118)
- Espindolol for the treatment and prevention of cachexia in patients with stage III/IV non‐small cell lung cancer or colorectal cancer: a randomized, double‐blind, placebo‐controlled, international multicentre phase II study (the ACT‐ONE trial) (2016) (118)
- Cancer diagnosis in patients with heart failure: epidemiology, clinical implications and gaps in knowledge (2018) (118)
- The obesity paradox in chronic disease: facts and numbers (2012) (114)
- Comparison of sarcopenia and cachexia in men with chronic heart failure: results from the Studies Investigating Co‐morbidities Aggravating Heart Failure (SICA‐HF) (2018) (111)
- Treatment of cachexia: An overview of recent developments. (2015) (109)
- Muscle wasting in heart failure: An overview. (2013) (106)
- Muscle wasting disease: a proposal for a new disease classification (2014) (103)
- Sodium Zirconium Cyclosilicate among Individuals with Hyperkalemia: A 12-Month Phase 3 Study. (2019) (100)
- The impact of iron deficiency and anaemia on exercise capacity and outcomes in patients with chronic heart failure. Results from the Studies Investigating Co-morbidities Aggravating Heart Failure. (2016) (99)
- Tumour necrosis factor-alpha and the failing heart--pathophysiology and therapeutic implications. (2004) (98)
- Inflammatory biomarkers in heart failure revisited: much more than innocent bystanders. (2009) (96)
- Cardiovascular function and predictors of exercise capacity in patients with colorectal cancer. (2014) (93)
- Prevalence, incidence, and prognostic value of anaemia in patients after an acute myocardial infarction: data from the OPTIMAAL trial. (2009) (91)
- Pharmacokinetics of Drugs in Cachectic Patients: A Systematic Review (2013) (91)
- Heat shock protein 70 in patients with chronic heart failure: relation to disease severity and survival. (2004) (90)
- Secretory sphingomyelinase is upregulated in chronic heart failure: a second messenger system of immune activation relates to body composition, muscular functional capacity, and peripheral blood flow. (2007) (89)
- Pathophysiologic quantities of endotoxin-induced tumor necrosis factor-alpha release in whole blood from patients with chronic heart failure. (2002) (88)
- Effect of interleukin-10 on the production of tumor necrosis factor-alpha by peripheral blood mononuclear cells from patients with chronic heart failure. (2002) (87)
- Testosterone Deficiency and Testosterone Treatment in Older Men (2016) (87)
- Orphan disease status of cancer cachexia in the USA and in the European Union: a systematic review (2019) (86)
- Cachexia: a therapeutic approach beyond cytokine antagonism. (2002) (85)
- Diabetes mellitus, cachexia and obesity in heart failure: rationale and design of the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF) (2010) (83)
- Prevalence and clinical impact of iron deficiency and anaemia among outpatients with chronic heart failure: The PrEP Registry (2017) (80)
- Natriuretic peptides and other biomarkers in chronic heart failure: from BNP, NT-proBNP, and MR-proANP to routine biochemical markers. (2009) (77)
- The gut and intestinal bacteria in chronic heart failure. (2009) (77)
- Differences between bisoprolol and carvedilol in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized trial. (2011) (76)
- Absolute and functional iron deficiency in professional athletes during training and recovery. (2012) (76)
- A NOVEL SELECTIVE EXTRACORPOREAL INTERVENTION IN SEPSIS: IMMUNOADSORPTION OF ENDOTOXIN, INTERLEUKIN 6, AND COMPLEMENT-ACTIVATING PRODUCT 5a (2007) (76)
- Dysfunction of respiratory muscles in critically ill patients on the intensive care unit (2016) (76)
- Statins and the Role of Nitric Oxide in Chronic Heart Failure (2004) (72)
- The relevance of congestion in the cardio-renal syndrome. (2013) (71)
- Sarcopenia, cachexia, and muscle performance in heart failure: Review update 2016. (2017) (70)
- Effects of statins on mitochondrial pathways (2021) (69)
- Catabolic Signaling and Muscle Wasting After Acute Ischemic Stroke in Mice: Indication for a Stroke-Specific Sarcopenia (2014) (68)
- Fluvastatin reduces increased blood monocyte Toll-like receptor 4 expression in whole blood from patients with chronic heart failure. (2008) (68)
- Metabolism and the heart: an overview of muscle, fat, and bone metabolism in heart failure. (2013) (67)
- Heart failure epidemiology and novel treatments in Japan: facts and numbers (2016) (66)
- Are we closer to having drugs to treat muscle wasting disease? (2014) (66)
- Changes in serum creatinine in the first 24 hours after cardiac arrest indicate prognosis: an observational cohort study (2009) (66)
- Resting heart rate is an independent predictor of death in patients with colorectal, pancreatic, and non‐small cell lung cancer: results of a prospective cardiovascular long‐term study (2016) (66)
- The relationship between tumor necrosis factor-α, brain natriuretic peptide and atrial natriuretic peptide in patients with chronic heart failure. (2010) (62)
- Highlights from the 7th Cachexia Conference: muscle wasting pathophysiological detection and novel treatment strategies (2014) (61)
- Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the Translational Research Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) (2020) (61)
- Iron deficiency in patients with heart failure with preserved ejection fraction and its association with reduced exercise capacity, muscle strength and quality of life (2018) (61)
- Weight loss, malnutrition, and cachexia in COVID‐19: facts and numbers (2020) (61)
- Ursodeoxycholic acid in patients with chronic heart failure: a double-blind, randomized, placebo-controlled, crossover trial. (2012) (60)
- Iron deficiency as energetic insult to skeletal muscle in chronic diseases (2018) (59)
- Plasma adiponectin in heart failure with and without cachexia: catabolic signal linking catabolism, symptomatic status, and prognosis. (2014) (59)
- Novel treatment approaches to cachexia and sarcopenia: highlights from the 5th Cachexia Conference (2010) (59)
- Serum chloride levels in critical illness—the hidden story (2018) (59)
- Muscle wasting: an overview of recent developments in basic research (2014) (57)
- The anabolic catabolic transforming agent (ACTA) espindolol increases muscle mass and decreases fat mass in old rats (2013) (56)
- Functional iron deficiency and diastolic function in heart failure with preserved ejection fraction. (2013) (55)
- Frailty and heart disease. (2013) (55)
- Inhibition of xanthine oxidase reduces wasting and improves outcome in a rat model of cancer cachexia (2012) (55)
- Anorexia, functional capacity, and clinical outcome in patients with chronic heart failure: results from the Studies Investigating Co‐morbidities Aggravating Heart Failure (SICA‐HF) (2017) (55)
- Copeptin as a prognostic factor for major adverse cardiovascular events in patients with coronary artery disease. (2012) (55)
- Mechanism and novel therapeutic approaches to wasting in chronic disease. (2013) (54)
- Sarcopenia and Endothelial Function in Patients With Chronic Heart Failure: Results From the Studies Investigating Comorbidities Aggravating Heart Failure (SICA-HF). (2017) (54)
- Onco-Cardiology: Consensus Paper of the German Cardiac Society, the German Society for Pediatric Cardiology and Congenital Heart Defects and the German Society for Hematology and Medical Oncology (2020) (53)
- Biomarkers for physical frailty and sarcopenia (2017) (53)
- Detection of muscle wasting in patients with chronic heart failure using C‐terminal agrin fragment: results from the Studies Investigating Co‐morbidities Aggravating Heart Failure (SICA‐HF) (2015) (53)
- Iron Deficiency in Heart Failure: A Practical Guide (2013) (53)
- Iron Status and Survival in Diabetic Patients With Coronary Artery Disease (2013) (53)
- Improving exercise capacity and quality of life using non‐invasive heart failure treatments: evidence from clinical trials (2020) (52)
- Megestrol acetate improves cardiac function in a model of cancer cachexia‐induced cardiomyopathy by autophagic modulation (2016) (52)
- Biomarkers, myocardial fibrosis and co-morbidities in heart failure with preserved ejection fraction: an overview (2018) (51)
- The burden of chronic obstructive pulmonary disease in patients hospitalized with heart failure (2009) (50)
- Inflammatory pathways in patients with heart failure and preserved ejection fraction. (2008) (50)
- TWIST1 regulates the activity of ubiquitin proteasome system via the miR-199/214 cluster in human end-stage dilated cardiomyopathy. (2013) (50)
- Nutrition in heart failure: an update (2009) (50)
- Growth hormone, insulin-like growth factor 1, and insulin signaling—a pharmacological target in body wasting and cachexia (2011) (49)
- The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study (2011) (49)
- IGF-1 treatment reduces weight loss and improves outcome in a rat model of cancer cachexia (2011) (48)
- Cancer Cachexia and Related Metabolic Dysfunction (2020) (48)
- Evaluation of C‐terminal Agrin Fragment as a marker of muscle wasting in patients after acute stroke during early rehabilitation (2015) (47)
- Association of adiponectin with peripheral muscle status in elderly patients with heart failure. (2013) (47)
- Cachexia as major underestimated unmet medical need: facts and numbers. (2012) (47)
- Simvastatin reduces wasting and improves cardiac function as well as outcome in experimental cancer cachexia. (2013) (46)
- Endothelial Dysfunction of the Peripheral Vascular Bed in the Acute Phase after Ischemic Stroke (2011) (45)
- Muscle wasting as an independent predictor of survival in patients with chronic heart failure (2020) (44)
- Treatment of cachexia: an overview of recent developments. (2014) (44)
- Protective overweight in cardiovascular disease: moving from 'paradox' to 'paradigm'. (2015) (43)
- Highlights of the mechanistic and therapeutic cachexia and sarcopenia research 2010 to 2012 and their relevance for cardiology. (2013) (43)
- The CD4+AT2R+ T cell subpopulation improves post-infarction remodelling and restores cardiac function (2015) (42)
- Rationale and design of the DIGIT‐HF trial (DIGitoxin to Improve ouTcomes in patients with advanced chronic Heart Failure): a randomized, double‐blind, placebo‐controlled study (2019) (42)
- Multicomponent intervention to prevent mobility disability in frail older adults: randomised controlled trial (SPRINTT project) (2022) (42)
- Identification of Chronic Heart Failure Patients with a High 12-Month Mortality Risk Using Biomarkers Including Plasma C-Terminal Pro-Endothelin-1 (2011) (41)
- Nutritional status and its effects on muscle wasting in patients with chronic heart failure: insights from Studies Investigating Co-morbidities Aggravating Heart Failure (2016) (40)
- Heart failure biomarkers in patients with dilated cardiomyopathy. (2013) (39)
- The xanthine oxidase inhibitor oxypurinol reduces cancer cachexia-induced cardiomyopathy. (2013) (39)
- Liver dysfunction and its nutritional implications in heart failure. (2013) (39)
- Cardiac cachexia is associated with right ventricular failure and liver dysfunction. (2013) (39)
- Elevated plasma levels of neuropeptide proenkephalin a predict mortality and functional outcome in ischemic stroke. (2012) (38)
- Exercise capacity and body composition in living-donor renal transplant recipients over time. (2009) (37)
- Leukocyte Redistribution: Effects of Beta Blockers in Patients with Chronic Heart Failure (2009) (37)
- Clustering of 37 circulating biomarkers by exploratory factor analysis in patients following complicated acute myocardial infarction. (2013) (37)
- Acylated ghrelin treatment normalizes skeletal muscle mitochondrial oxidative capacity and AKT phosphorylation in rat chronic heart failure (2017) (37)
- Inflammation in right ventricular dysfunction due to thromboembolic pulmonary hypertension. (2010) (36)
- Tele-accelerometry as a novel technique for assessing functional status in patients with heart failure: feasibility, reliability and patient safety. (2013) (36)
- Bone marrow iron depletion is common in patients with coronary artery disease. (2015) (36)
- Insulin resistance in heart failure: differences between patients with reduced and preserved left ventricular ejection fraction (2015) (36)
- Future prospects of anticytokine therapy in chronic heart failure (2005) (35)
- Advances in understanding and treating cardiac cachexia: highlights from the 5th Cachexia Conference. (2010) (35)
- Heart failure in the last year: progress and perspective (2020) (35)
- Elevated TNFα production in whole blood in patients with severe COPD: the potential link to disease severity (2009) (34)
- A prospective study of the associations between 25‐hydroxyvitamin D, sarcopenia progression and physical activity in older adults (2011) (34)
- Cardiac Cachexia Revisited: The Role of Wasting in Heart Failure. (2020) (33)
- Nutraceutical support in heart failure: a position paper of the International Lipid Expert Panel (ILEP) (2020) (33)
- Molecular mechanisms and treatment targets of muscle wasting and cachexia in heart failure: an overview (2014) (32)
- Unlocking the wasting enigma: Highlights from the 8th Cachexia Conference (2016) (32)
- Biomarkers and Echocardiographic Predictors of Myocardial Dysfunction in Patients with Hypertension (2014) (31)
- Tipping the scale: heart failure, body mass index, and prognosis. (2007) (31)
- Hormonal consequences and prognosis of chronic heart failure (2011) (31)
- Cancer and heart failure—more than meets the eye: common risk factors and co‐morbidities (2018) (30)
- Nutrition in cachexia: from bench to bedside (2016) (30)
- Differences in biochemical and genetic biomarkers in patients with heart failure of various etiologies. (2016) (30)
- Recent advances in cardio‐oncology: a report from the ‘Heart Failure Association 2019 and World Congress on Acute Heart Failure 2019’ (2019) (30)
- Models of sarcopenia: Short review. (2017) (29)
- Subclinical hypothyroidism and the development of heart failure: an overview of risk and effects on cardiac function (2018) (29)
- Skeletal muscle weakness is related to insulin resistance in patients with chronic heart failure (2015) (29)
- Cachexia in heart disease: highlights from the ESC 2010 (2011) (29)
- Long-term safety and efficacy of sodium zirconium cyclosilicate for hyperkalaemia in patients with mild/moderate versus severe/end-stage chronic kidney disease: comparative results from an open-label, Phase 3 study (2020) (28)
- Interleukin-6 serum level assessment using a new qualitative point-of-care test in sepsis: A comparison with ELISA measurements. (2008) (28)
- Resting energy expenditure and the effects of muscle wasting in patients with chronic heart failure: results from the Studies Investigating Comorbidities Aggravating Heart Failure (SICA-HF). (2013) (28)
- The influence of atorvastatin on parameters of inflammation left ventricular function, hospitalizations and mortality in patients with dilated cardiomyopathy – 5-year follow-up (2013) (28)
- The cholesterol paradox revisited: heart failure, systemic inflammation, and beyond. (2008) (27)
- The influence of age and sex on disease development in a novel animal model of cardiac cachexia. (2009) (27)
- Tandospirone reduces wasting and improves cardiac function in experimental cancer cachexia. (2013) (27)
- Neurohormonal activation and inflammation in chronic cardiopulmonary disease: a brief systematic review (2009) (27)
- Mortality and morbidity 1 year after stopping a remote patient management intervention: extended follow-up results from the telemedical interventional management in patients with heart failure II (TIM-HF2) randomised trial. (2020) (26)
- Nutrition in the spotlight in cachexia, sarcopenia and muscle: avoiding the wildfire (2020) (26)
- Body weight changes and incidence of cachexia after stroke (2018) (26)
- Febuxostat improves outcome in a rat model of cancer cachexia (2015) (26)
- Investigation of changes in body composition, metabolic profile and skeletal muscle functional capacity in ischemic stroke patients: the rationale and design of the Body Size in Stroke Study (BoSSS) (2013) (26)
- Ursodeoxycholic acid treatment in a rat model of cancer cachexia (2011) (25)
- Effect of noradrenaline and isoproterenol on lipopolysaccharide-induced tumor necrosis factor-alpha production in whole blood from patients with chronic heart failure and the role of beta-adrenergic receptors. (2005) (24)
- Impact of Plasma Kynurenine Level on Functional Capacity and Outcome in Heart Failure - Results From Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF). (2016) (24)
- Recent developments in the treatment of cachexia: highlights from the 6th Cachexia Conference (2012) (23)
- Systemic changes of tryptophan catabolites via the indoleamine-2,3-dioxygenase pathway in primary cervical cancer. (2011) (23)
- A current and future outlook on upcoming technologies in remote monitoring of patients with heart failure (2020) (22)
- Animal models of cachexia and sarcopenia in chronic illness: Cardiac function, body composition changes and therapeutic results. (2017) (22)
- Cardio-renal anemia syndrome. (2011) (22)
- Recent developments in the field of cachexia, sarcopenia, and muscle wasting: highlights from the 11th Cachexia Conference (2019) (22)
- Uric acid in CHF: marker or player in a metabolic disease? (2007) (22)
- Prognostic performance of serial in‐hospital measurements of copeptin and multiple novel biomarkers among patients with worsening heart failure: results from the MOLITOR study (2018) (22)
- Cachexia research in Japan: facts and numbers on prevalence, incidence and clinical impact (2016) (21)
- Value of serum pregnancy-associated plasma protein A for predicting cardiovascular events among patients presenting with cardiac chest pain (2013) (21)
- Modern‐day cardio‐oncology: a report from the ‘Heart Failure and World Congress on Acute Heart Failure 2018’ (2018) (21)
- The small intestine: a critical linkage in pathophysiology of cardiac cachexia. (2011) (21)
- Anemia in heart failure: an overview of current concepts. (2011) (20)
- Iron deficiency in heart failure (2021) (20)
- Micronutrient Depletion in Heart Failure: Common, Clinically Relevant and Treatable (2019) (20)
- Identification and regulation of the long non-coding RNA Heat2 in heart failure. (2019) (20)
- Obesity and the heart a weighty issue. (2006) (20)
- Relationship between skeletal muscle mass and cardiac function during exercise in community‐dwelling older adults (2017) (19)
- Effect of beta blockade on natriuretic peptides and copeptin in elderly patients with heart failure and preserved or reduced ejection fraction: results from the CIBIS-ELD trial. (2012) (19)
- Prognostic impact of muscle and fat mass in patients with heart failure (2021) (18)
- Effect of application route of the ghrelin analog BIM-28131 (RM-131) on body weight and body composition in a rat heart failure model. (2013) (18)
- Role of iron deficiency and anemia in cardio-renal syndromes. (2012) (18)
- Rosiglitazone reduces body wasting and improves survival in a rat model of cancer cachexia. (2014) (18)
- Association of statin use and clinical outcomes in heart failure patients: a systematic review and meta-analysis (2019) (18)
- Prosarcopenic Effects of Statins May Limit Their Effectiveness in Patients with Heart Failure. (2018) (18)
- Sibutramine in cardiovascular disease: is SCOUT the new STORM on the horizon? (2007) (17)
- Diminished HLA-DR expression on monocyte and dendritic cell subsets indicating impairment of cellular immunity in pre-term neonates: a prospective observational analysis (2015) (17)
- An overview of recent developments in the treatment of heart failure: update from the ESC Congress 2013 (2014) (17)
- Neuromuscular electrical stimulation for muscle wasting in heart failure patients. (2016) (17)
- Developing models for cachexia and their implications in drug discovery (2015) (17)
- Risk stratification in patients with chronic heart failure based on metabolic-immunological, functional and haemodynamic parameters. (2012) (17)
- Erythropoietin levels in heart failure after an acute myocardial infarction: determinants, prognostic value, and the effects of captopril versus losartan. (2009) (16)
- Higher serum phosphorus is associated with catabolic/anabolic imbalance in heart failure (2015) (16)
- Cachexia vs obesity: where is the real unmet clinical need? (2013) (16)
- Selective androgen receptor modulators (SARMs) as pharmacological treatment for muscle wasting in ongoing clinical trials (2020) (16)
- Does obesity make it better or worse: insights into cardiovascular illnesses. (2013) (16)
- Sleep‐Disordered Breathing in Acute Ischemic Stroke: A Mechanistic Link to Peripheral Endothelial Dysfunction (2017) (15)
- Muscle wasting in heart failure (2016) (15)
- Therapeutic considerations of sarcopenia in heart failure patients (2018) (15)
- The wasting continuum in heart failure: from sarcopenia to cachexia (2015) (15)
- Bone in heart failure (2020) (15)
- Could gonadal and adrenal androgen deficiencies contribute to the depressive symptoms in men with systolic heart failure? (2016) (15)
- The sarcopenia and physical frailty in older people: multi-component treatment strategies (SPRINTT) project: description and feasibility of a nutrition intervention in community-dwelling older Europeans (2021) (15)
- Toll-like receptor modulation in cardiovascular disease: a target for intervention? (2006) (15)
- Improved insulin sensitivity by the angiotensin receptor antagonist irbesartan in patients with systolic heart failure: a randomized double-blinded placebo-controlled study. (2012) (14)
- Should procalcitonin be measured routinely in acute decompensated heart failure? (2015) (14)
- Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial. (2021) (14)
- Effects of Dialysis Modality on Blood Loss, Bleeding Complications and Transfusion Requirements in Critically Ill Patients with Dialysis-Dependent Acute Renal Failure (2015) (14)
- Weight reduction in patients with coronary artery disease: comparison of Traditional Tibetan Medicine and Western diet. (2013) (14)
- Usefulness of minimal modelling to assess impaired insulin sensitivity in patients with chronic heart failure. (2011) (14)
- Ferric carboxymaltose for the treatment of iron‐deficient heart failure patients: a systematic review and meta‐analysis (2020) (14)
- Muscle wasting and sarcopenia in heart failure: a brief overview of the current literature (2018) (14)
- Recent developments in the field of cachexia, sarcopenia, and muscle wasting: highlights from the 12th Cachexia Conference (2020) (13)
- Single baseline serum creatinine measurements predict mortality in critically ill patients hospitalized for acute heart failure (2015) (13)
- Impact of body mass index on in-hospital outcomes following percutaneous coronary intervention. (2004) (13)
- Influence of essential amino acids on muscle mass and muscle strength in patients with cerebral stroke during early rehabilitation: protocol and rationale of a randomized clinical trial (AMINO-Stroke Study) (2016) (13)
- Efforts begin to sprout: publications in JCSM on cachexia, sarcopenia and muscle wasting receive attention (2014) (13)
- Pleiotropic Effects of Angiotensin‐Converting Enzyme Inhibitors and the Future of Cachexia Therapy (2005) (13)
- Insulin resistance in chronic heart failure. (2008) (13)
- Highlights of mechanistic and therapeutic cachexia and sarcopenia research 2010 to 2012 and their relevance for cardiology (2013) (13)
- Effects of Early Empagliflozin Initiation on Diuresis and Kidney Function in Patients With Acute Decompensated Heart Failure (EMPAG-HF) (2022) (13)
- Vitamin D in chronic kidney disease: more questions than answers. (2012) (13)
- Promising models for cancer-induced cachexia drug discovery (2020) (12)
- Furosemide induces mortality in a rat model of chronic heart failure. (2012) (12)
- Adjuvant breast cancer treatments cardiotoxicity and modern methods of detection and prevention of cardiac complications (2021) (12)
- Sleep‐disordered breathing in heart failure: facts and numbers (2017) (12)
- Cardiotoxicity and Cardiovascular Biomarkers in Patients With Breast Cancer: Data From the GeparOcto‐GBG 84 Trial (2020) (12)
- Sleep-disordered breathing and cardiovascular disease (2015) (12)
- Lipopolysaccharide responsiveness is an independent predictor of death in patients with chronic heart failure. (2015) (11)
- An overview of anamorelin as a treatment option for cancer-associated anorexia and cachexia (2021) (11)
- The role of micronutrients and macronutrients in patients hospitalized for heart failure. (2013) (11)
- Mid-regional pro-atrial natriuretic peptide as a prognostic marker for all-cause mortality in patients with symptomatic coronary artery disease. (2012) (11)
- Decreased Appendicular Skeletal Muscle Mass is Associated with Poor Outcomes after ST-Segment Elevation Myocardial Infarction (2020) (11)
- Biomarkers for chronic heart failure. (2007) (11)
- MT‐102 prevents tissue wasting and improves survival in a rat model of severe cancer cachexia (2020) (10)
- Silver linings on the horizon: highlights from the 10th Cachexia Conference (2018) (10)
- Muscle wasting: an overview of recent developments in basic research. (2014) (10)
- Cardiac expression of neutrophil gelatinase‐associated lipocalin in a model of cancer cachexia‐induced cardiomyopathy (2018) (10)
- Non-invasive assessment of cardiac hemodynamics in patients with advanced cancer and with chronic heart failure: a pilot feasibility study (2013) (10)
- Atorvastatin modulates Th1/Th2 response in patients with chronic heart failure. (2009) (10)
- Iron deficiency and cardiovascular disease (2022) (10)
- Co‐morbidities in heart failure beginning to sprout—and no end in sight? (2017) (10)
- Influence of core body temperature on Tryptophan metabolism, kynurenines, and estimated IDO activity in critically ill patients receiving target temperature management following cardiac arrest. (2016) (10)
- More colour to the Journal: new style, new publisher, but still Cachexia, Sarcopenia and Muscle (2015) (9)
- Activation of the NF-kappaB system in peripheral blood leukocytes from patients with chronic heart failure. (2005) (9)
- The influence of confounders in the analysis of mid-regional pro-atrial natriuretic peptide in patients with chronic heart failure. (2016) (9)
- Highlights from the 9th Cachexia Conference (2017) (9)
- Morbidity and mortality in patients with cardiovascular risk factors and obstructive sleep apnoea: results from the DIAST-CHF cohort. (2019) (9)
- Androgen status in non-diabetic elderly men with heart failure (2017) (9)
- Assessment of baroreflex sensitivity has no prognostic value in contemporary, optimally managed patients with mild‐to‐moderate heart failure with reduced ejection fraction: a retrospective analysis of 5‐year survival (2018) (9)
- Inferior vena cava ultrasound in acute decompensated heart failure: design rationale of the CAVA‐ADHF‐DZHK10 trial (2020) (9)
- Abnormal serum calcium levels are associated with clinical response to maximization of heart failure therapy. (2015) (8)
- A year in heart failure: an update of recent findings (2021) (8)
- The beneficial therapeutic effects of plant‐derived natural products for the treatment of sarcopenia (2022) (8)
- The relationship between age and production of tumour necrosis factor-alpha in healthy volunteers and patients with chronic heart failure. (2003) (8)
- Erythropoietin improves cardiac wasting and outcomes in a rat model of liver cancer cachexia. (2016) (8)
- Pathophysiological mechanisms of statin‐associated myopathies: possible role of the ubiquitin‐proteasome system (2020) (8)
- Muscle wasting in heart failure : The role of nutrition. (2016) (8)
- [Iron Deficiency in Chronic Heart Failure: Diagnostic Algorithm and Present-Day Therapeutic Options]. (2017) (8)
- Anaemia predicts health related quality of life in heart failure patients. (2013) (7)
- [Iron deficiency in chronic heart failure: from diagnosis to therapy]. (2014) (7)
- Statins: a treatment option for chronic heart failure? (2004) (7)
- Early rehabilitation after stroke: relationship between the heart rate variability and functional outcome (2020) (7)
- Atrial disease and heart failure: the common soil hypothesis proposed by the Heart Failure Association of the European Society of Cardiology. (2021) (7)
- Defining terms commonly used in sarcopenia research: a glossary proposed by the Global Leadership in Sarcopenia (GLIS) Steering Committee (2022) (7)
- The Journal of Cachexia, Sarcopenia and Muscle stays the front‐runner in geriatrics and gerontology (2019) (7)
- The appropriate dose of angiotensin‐converting‐enzyme inhibitors or angiotensin receptor blockers in patients with dilated cardiomyopathy. The higher, the better? (2015) (7)
- Why is Iron Deficiency Recognised as an Important Comorbidity in Heart Failure? (2019) (7)
- The times they are a‐changin’: the Cachexia Conference goes annual (2016) (7)
- Mid-regional proadrenomedullin levels predict recurrence of atrial fibrillation after catheter ablation. (2015) (7)
- Copeptin--a novel marker in acute myocardial infarction. (2012) (7)
- Arterial Stiffness and Indices of Left Ventricular Diastolic Dysfunction in Patients with Embolic Stroke of Undetermined Etiology (2019) (6)
- Serum phosphorus level is related to degree of clinical response to up-titration of heart failure pharmacotherapy. (2014) (6)
- Early identification of acute heart failure at the time of presentation: do natriuretic peptides make the difference? (2018) (6)
- Heart failure with preserved ejection fraction in coronavirus disease 2019 patients: the promising role of diuretic therapy in critically ill patients (2021) (6)
- [Indications and Clinical Implications of the Use of the Cardiac Markers BNP and NT-proBNP]. (2017) (6)
- [Iron deficiency : Recognition and treatment]. (2017) (6)
- Blocking myostatin: muscle mass equals muscle strength? (2020) (6)
- Safety and Efficacy of Intravenous Ferric Derisomaltose Compared to Iron Sucrose for Iron Deficiency Anemia in Patients with Chronic Kidney Disease With and Without Heart Failure. (2021) (6)
- Andropausal syndrome in men with systolic heart failure. (2013) (6)
- [Immunactivation in chronic heart failure. Inflammatory mediators]. (2004) (6)
- Landiolol for rate control management of atrial fibrillation in patients with cardiac dysfunction (2018) (5)
- Longer-term impact of hemiparetic stroke on skeletal muscle metabolism-A pilot study. (2017) (5)
- Oodles of opportunities: the Journal of Cachexia, Sarcopenia and Muscle in 2017 (2017) (5)
- Weight change with beta-blocker use: a side effect put into perspective. (2008) (5)
- beta-blockers in heart failure--much more than heart rate reduction. (2002) (5)
- Overview of emerging pharmacotherapy in chronic heart failure (2009) (5)
- Critical appraisal of the 2020 ESC guideline recommendations on diagnosis and risk assessment in patients with suspected non-ST-segment elevation acute coronary syndrome (2021) (5)
- Bariatric Surgery or Intensive Medical Therapy for Diabetes after 5 Years. (2017) (5)
- Iohexol clearance is superior to creatinine-based renal function estimating equations in detecting short-term renal function decline in chronic heart failure (2015) (5)
- Iron deficiency is related to low functional outcome in patients at early rehabilitation after acute stroke (2022) (5)
- Hypokalaemia and outcomes in older patients hospitalized for heart failure (2020) (5)
- Moving upwards – the journal of cachexia, sarcopenia and muscle in 2016 (2016) (5)
- The fatter, the better in old age: the current understanding of a difficult relationship. (2021) (5)
- The 6th Cachexia Conference: an introduction to clinical and basic research in an exiting area (2011) (5)
- PURE muscle and more. (2016) (4)
- Muscle in heart disease: highlights from the European Society of Cardiology's Annual Meeting 2012. (2012) (4)
- Iron deficiency in heart failure (2018) (4)
- Impact of levosimendan treatment on chronic heart failure. (2004) (4)
- Time to jump on the bandwagon: the Journal of Cachexia, Sarcopenia and Muscle in 2018 (2018) (4)
- Increased Activity of the Immunoregulatory Enzyme Indoleamine-2,3-Dioxygenase with Consecutive Tryptophan Depletion Predicts Death in Patients with Neuroendocrine Neoplasia (2016) (4)
- Central Chemoreceptor Sensitivity Is Not Enhanced in Contemporary Patients With Chronic Systolic Heart Failure Receiving Optimal Treatment. (2017) (4)
- Moving on up: the Journal of Cachexia, Sarcopenia and Muscle (2015) (4)
- Heart failure: an update from the last years and a look at the near future (2022) (4)
- ACC/AHA/HFSA 2022 and ESC 2021 guidelines on heart failure comparison. (2022) (3)
- [Biomarkers in acute medicine]. (2019) (3)
- Casting the net broader to confirm our imaginations: the long road to treating wasting disorders (2017) (3)
- Targeting the toll-system in cardiovascular sciences. (2007) (3)
- Estimating fat mass in heart failure patients (2016) (3)
- Treatment of Muscle Wasting: An Overview of Promising Treatment Targets. (2015) (3)
- Adding insult to injury: heart failure and incident cancer (2016) (3)
- Spontaneous Non-Sustained Ventricular Tachycardia and Premature Ventricular Contractions and Their Prognostic Relevance in Patients with Cancer in Routine Care (2021) (3)
- Cardiac hepatopathy versus end-stage liver disease: two different entities. (2014) (3)
- No train, no gain: does this apply to heart failure with preserved ejection fraction? (2013) (3)
- Metabolomic Profiling in Patients with Heart Failure and Exercise Intolerance: Kynurenine as a Potential Biomarker (2022) (2)
- Novel biomarkers in heart failure and cardio-oncology. (2019) (2)
- Heart failure and sleep‐disordered breathing: susceptibility to reduced muscle strength and preclinical congestion (SICA‐HF cohort) (2020) (2)
- Iron deficiency and risk of early readmission following a hospitalization for acute heart failure (2016) (2)
- Muscle mass, muscle strength, and functional capacity in patients with heart failure of Chagas disease and other aetiologies (2020) (2)
- Statins for heart failure: still caught in no man's land? (2009) (2)
- Sarcopaenia complicating heart failure (2019) (2)
- [Cachexia and sarcopenia in chronic heart failure : Change in muscle strength and muscle structure]. (2018) (2)
- Pharmacological treatment options for heart failure with reduced ejection fraction: A 2022 update (2022) (2)
- Sarcopenia and cachexia in chronic diseases: from mechanisms to treatment. (2021) (2)
- Concerning the Role of Gender Difference in Obesity Paradox in Patients With Heart Failure. (2016) (2)
- Acute effects of oral triglyceride load on dynamic changes in peripheral endothelial function in heart failure patients with reduced ejection fraction and healthy controls. (2020) (2)
- Iron Deficiency and Reduced Muscle Strength in Patients with Acute and Chronic Ischemic Stroke (2022) (2)
- The roles of immunity and autoimmunity in chronic heart failure. (2006) (2)
- Elevated PAPP-A sets alarm bells ringing in patients with cardiac chest pain (2014) (2)
- More variety with the Journal of Cachexia, Sarcopenia and Muscle: JCSM Clinical Reports and JCSM Rapid Communications have both gone live (2018) (2)
- Weight Loss and Health Status after Bariatric Surgery in Adolescents. (2016) (2)
- The evolving obesity paradigm story: from heart failure to atrial fibrillation. (2019) (2)
- Updates in heart failure: Highlights from the Iranian Joint Cardiovascular Congress Tehran, Iran, 1-4 March 2016. (2017) (2)
- The erythropoietin‐derived peptide ARA 284 reduces tissue wasting and improves survival in a rat model of cancer cachexia (2022) (1)
- Sarcopenia and Frailty in Heart Failure: Is There a Biomarker Signature? (2022) (1)
- Biomarkers-in-Cardiology 8 RE-VISITED—Consistent Safety of Early Discharge with a Dual Marker Strategy Combining a Normal hs-cTnT with a Normal Copeptin in Low-to-Intermediate Risk Patients with Suspected Acute Coronary Syndrome—A Secondary Analysis of the Randomized Biomarkers-in-Cardiology 8 Trial (2022) (1)
- Cardiovascular magnetic resonance imaging patterns of acute COVID-19 mRNA vaccine-associated myocarditis in young male patients: A first single-center experience (2022) (1)
- The muscle in dire straits: mechanisms of wasting in heart failure. (2012) (1)
- The Journal of Cachexia, Sarcopenia and Muscle in 2019 (2019) (1)
- Soluble ST2 Receptor: Biomarker of Left Ventricular Impairment and Functional Status in Patients with Inflammatory Cardiomyopathy (2022) (1)
- Once I get on a puzzle, I can't get off: Cachexia and wasting in 2018 (2018) (1)
- From meta‐analysis to Cochrane reviews (2018) (1)
- Wasting away: How to treat cachexia and muscle wasting in chronic disease? (2017) (1)
- Clinical and Prognostic Relevance of Cardiac Wasting in Patients With Advanced Cancer. (2023) (1)
- Nutrient pattern analysis in critically ill patients using Omics technology (NAChO) – Study protocol for a prospective observational study (2019) (1)
- [Cardiovascular fitness in oncology : Exercise and sport]. (2020) (1)
- Erratum to: Recent developments in the treatment of cachexia: highlights from the 6th Cachexia Conference (2012) (1)
- Travelling with heart failure: risk assessment and practical recommendations (2022) (1)
- Recent developments in the treatment of heart failure: highlights from the American Heart Association's Scientific Sessions, Los Angeles, California, 3 – 7 December 2012 (2013) (1)
- D3‐Creatine dilution for body composition assessment: A direct take on the matter (2022) (1)
- Diabetes and Heart Failure: Sugared Words Prove Bitter. (2016) (1)
- [The relevance of biomarkers in acute heart failure]. (2019) (1)
- Iron and Exercise in Heart Failure: How to Assess Relevant Changes? (2016) (1)
- Revisiting the obesity paradox in heart failure: what is the best anthropometric index to gauge obesity? (2023) (1)
- Annual Meeting of the American Heart Association (2006) (1)
- Losartan: the dose does it (2010) (0)
- Glucose-Induced Hemodynamic and Metabolic Response of Skeletal Muscle in Heart Failure Patients with Reduced vs. Preserved Ejection Fraction—A Pilot Study (2022) (0)
- The European Society of Cardiology working group on heart failure: Heart Failure Update 2003. (2003) (0)
- [Tumor effects on the heart and circulation]. (2020) (0)
- Efficacy and safety of intravenous iron repletion in patients with heart failure: a systematic review and meta-analysis (2023) (0)
- Bone status in men with heart failure: results from the Studies Investigating Co-morbidities Aggravating Heart Failure. (2023) (0)
- In reply: Treatment of cachexia: An overview of recent developments. (2015) (0)
- Effect of Intravenous Iron Replacement on Recurrent Heart Failure Hospitalizations and Cardiovascular Mortality in Patients with Heart Failure and Iron Deficiency: A Bayesian Meta-Analysis. (2023) (0)
- The small molecule ACM-001 improves cardiac function in a rat model of severe cancer cachexia. (2023) (0)
- The 10th year of the Journal of Cachexia, Sarcopenia and Muscle (2020) (0)
- Correction to: Association of statin use and clinical outcomes in heart failure patients: a systematic review and meta-analysis (2020) (0)
- Publishing in a heart failure journal—where lies the scientific interest? (2017) (0)
- Birth weight and heart failure: hindsight as an exact science? (2022) (0)
- Aortic valve calcification and myocardial fibrosis determine outcome following transcatheter aortic valve replacement. (2021) (0)
- Factors and Prognostic Significance of Impaired Exercise Tolerance in Women over 40 with Arterial Hypertension (2021) (0)
- A year in heart failure: updates of clinical and preclinical findings. (2023) (0)
- JCSM: growing together with cachexia and sarcopenia research (2021) (0)
- The American Heart Association's Scientific Sessions 2006. Chicago, IL, November 12-15, 2006. (2007) (0)
- The European Society of Cardiology (ESC) Annual Meeting 2005. (2005) (0)
- Cardiac Cachexia Revisited: The Role of Wasting in Heart Failure. (2022) (0)
- Furnishing the cachexia landscape: A year of research in JCSM (2022) (0)
- Worsening of chronic heart failure: definition, epidemiology, management and prevention. A clinical consensus statement by the Heart Failure Association ( HFA ) of the ESC (2023) (0)
- [Comorbidities in heart failure : An interdisciplinary challenge]. (2018) (0)
- Association of peripheral edema on body composition analysis in patients with heart failure (2022) (0)
- Trial of lorcaserin for weight management. (2010) (0)
- Role of Copeptin and hs-cTnT to Discriminate AHF from Uncomplicated NSTE-ACS with Baseline Elevated hs-cTnT—A Derivation and External Validation Study (2023) (0)
- Open access efforts begin to bloom: ESC Heart Failure gets full attention and first impact factor (2019) (0)
- Skeletal muscle derived Musclin protects the heart during pathological overload (2022) (0)
- The new Heart Failure Association journal – ESC Heart Failure (2018) (0)
- Abstract 10499: The Heart Failure-Induced Long Non-Coding RNA Heat4 Reduces the Inflammatory Response of Non-Classical Monocytes and Mediates Regeneration After Vascular Injury (2021) (0)
- [Cardio-oncology: At the crossroads between two fields]. (2020) (0)
- The atypical β‐blocker S‐oxprenolol reduces cachexia and improves survival in a rat cancer cachexia model (2022) (0)
- Battlescarred: subgroup or selection bias? (2010) (0)
- The influence of atorvastatin on parameters of inflammation left ventricular function, hospitalizations and mortality in patients with dilated cardiomyopathy – 5-year follow-up (2013) (0)
- Effects of a 2‐year exercise training on neuromuscular system health in older individuals with low muscle function (2023) (0)
- Current advancements in pharmacotherapy for cancer cachexia (2023) (0)
- ESC Heart Failure increases its impact factor (2020) (0)
- Correction to: Association of statin use and clinical outcomes in heart failure patients: a systematic review and meta-analysis (2020) (0)
- Cardiovascular and metabolic determinants of quality of life in patients with cancer (2022) (0)
- Association of statin use and clinical outcomes in heart failure patients: a systematic review and meta-analysis (2019) (0)
- Creating an impact, not an impression: ESC Heart Failure in its seventh year (2021) (0)
- ESC Heart Failure: a new journal aims to broaden heart failure views (2016) (0)
- Reply: Cardiovascular function and exercise capacity in patients with colorectal cancer: does anticancer therapy matter? (2015) (0)
This paper list is powered by the following services:
